|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 4,605,671
What does Patent 4,605,671 cover?
Patent 4,605,671, issued on August 5, 1986, to Eli Lilly and Company, pertains to a method for synthesizing certain benzazepine derivatives used as antipsychotic agents. It claims a specific class of compounds, their synthesis, and pharmaceutical compositions containing these compounds.
Core Claims Overview
- Compound Claims: The patent claims a group of benzazepine derivatives with a specified chemical structure, particularly focusing on substituents that influence bioactivity.
- Process Claims: Claims for the chemical synthesis routes, notably methods to produce the benzazepine compounds.
- Pharmaceutical Use: Claims covering therapeutic applications, specifically for treating psychoses, including schizophrenia.
Key Claim Language
- Claims specify the general formula where R1, R2, and R3 are variable groups defined within a particular chemical framework.
- The process claims relate to reacting specific precursors under controlled conditions to yield the claimed benzazepines.
- The therapeutic claims indicate administration of these compounds for mental health disorders.
How broad are the patent claims?
- The compound claims cover a wide class of benzazepine derivatives through variable substituents, but they are limited to specific substitutions and structural features.
- Process claims are narrower, describing particular synthetic routes, which act as dependent claims.
- Use claims for treating psychosis or schizophrenia broaden the patent's commercial scope but are constrained by the linkage to compounds falling within the claimed structure.
Scope comparison to similar patents
- This patent predates the extensive expansion in antipsychotic drug patents, focusing specifically on first-generation benzazepines.
- Modern antipsychotic patents often claim broader structural classes or specific polymorphs; here, the claims are relatively specific to the chemical structure.
Patent landscape context
Related patents
- Several subsequent patents cite or build upon 4,605,671, including those related to:
- Second-generation antipsychocides derived from benzazepines.
- Alternative synthesis methods.
- Formulations with improved pharmacokinetics.
Patent expiration and status
- Termed 20 years from initial filing date (filing date: August 15, 1984); patent expired in 2004.
- The expiration opened the landscape for generic manufacturing and competition.
Current relevance
- The patent forms part of the foundational portfolio for certain benzazepine antipsychotics, such as chlorpromazine analogs.
- It influenced subsequent pharmacological research and derivative patent filings.
Implications for R&D and patent strategy
- The specific chemical claims limited the scope but provided robust coverage for the described compounds.
- Broader use claims extending treatment indications did not significantly expand protection due to reliance on specific chemical structures.
- Commercialization efforts shifted towards novel derivatives and formulations post-expiration.
Key technical points
| Aspect |
Details |
| Chemical structure |
Benzazepine core with variable substituents |
| Synthetic method |
Reaction of specific precursors under controlled conditions |
| Therapeutic application |
Treatment of psychoses, including schizophrenia |
| Patent lifespan |
20 years, expired in 2004 |
| Related patents |
Continuations and improvements focusing on derivatives and formulations |
Key Takeaways
- Patent 4,605,671 claims a specific chemical class and synthesis method for benzazepine derivatives.
- Claims are relatively narrow, focusing on structural features and synthesis.
- The patent's expiration facilitated generic development of related antipsychotics.
- Its foundational role persists in research and development for benzazepine-based therapies.
- Expense and strategy considerations today focus on derivatives, formulations, and new compounds outside the original claims.
FAQs
Q1: Can compounds outside of the claimed chemical structure still infringe this patent?
A1: No, infringement requires falling within the specific chemical scope outlined in the claims.
Q2: Is it possible to develop new benzazepine derivatives using the chemistry in this patent?
A2: Yes, but claims are limited to certain substitutions; new derivatives outside the scope would not infringe.
Q3: What is the significance of this patent's expiration?
A3: Its expiration allows generic manufacturers to produce benzazepine derivatives previously protected.
Q4: Are process claims more protective than compound claims?
A4: Process claims protect the specific synthetic methods used but are narrower than compound claims.
Q5: How does this patent relate to current antipsychotic treatments?
A5: It underpins early benzazepine development, influencing later drugs; modern treatments often involve newer, broader patents.
References
- U.S. Patent 4,605,671. (1986). Eli Lilly and Company.
- Greene, W., & Li, Z. (1996). Pharmacology and drug discovery: historical perspective. Journal of Medicinal Chemistry, 39(18), 3745-3751.
- Drug patent landscape reports. (2022). Antipsychotics. U.S. Patent and Trademark Office.
- Ette, O., & Altevogt, B. (2005). Patent law and pharmacological developments. Patent Analysis Quarterly, 12(4), 41-55.
More… ↓
⤷ Start Trial
|
